More

    Good news Peter Thiel and Count Dracula, you can buy blood again



    %%

    Gimme dat sweet, sweet young plasma.

    Image: Ozge Elif Kizil/Anadolu Agency/Getty Images

    By Rachel Kraus

    Scientific evidence and federal approval be damned: young blood is back on the menu.

    Ambrosia, the company that sold plasma transfusions from donors aged 16-25 with the promise of youthful health benefits, shuttered its doors in August after the FDA issued a warning.

    Now, according to a report published Friday by Medium’s OneZero, Ambrosia is back in business.

    “Our patients really want the treatment,” Jesse Karamazin, Ambrosia’s founder, told One Zero.

    Ambrosia charges $8,000 for a one liter transfusion of plasma from “young blood,” which it claims can reduce the effects of aging. There is no scientific evidence to back up this claim, which is why the FDA “caution[ed] consumers against receiving young donor plasma infusions that are promoted as unproven treatment for varying conditions.”

    This type of plasma does have an approved on-label use: it helps prevent blood clotting in older patients. However, the off-label use is not approved by the FDA, and it stated in February that young plasma transfusions for non-approved reasons should only be conducted as part of scientific studies (also known as Investigational New Drug trials, or INDs). 

    In August, this was apparently enough to discourage Karamazin. He wrote a letter to people and publications who contacted the website (including Mashable) notifying them that Ambrosia would be no more.

    “In February, the FDA announced that off-label young plasma treatments should be performed only under IND. As a result, Ambrosia, LLC was dissolved. I am sorry that I wasn’t able to find a way for this company to continue its innovative treatments.”

    However, he did open a new blood transfusion business called Ivy Plasma. The decision to shut down your business due to government warnings, only to open a nearly identical business with a different name, is truly wild. 

    Now, it’s not clear what changed, other than Karamazin presumably deciding that he just didn’t care what the FDA had to say.

    Karamazin also has no plans to go through official channels to validate his plasma business.

    “This treatment is available now,” he told One Zero. “Trials are very expensive, and they take a really long time.”

    Yep, that checks out. Peter Thiel must be thrilled.

    %%

    - Advertisement -

    RELATED ARTICLES

    Recent Articles

    Technologies and scientific advances needed to track methane levels in atmosphere

    %%item_media%%Understanding what influences the amount of methane in the atmosphere has been identified to be one of the foremost challenges in the earth sciences...

    Chiton mollusk provides model for new armor design

    %%item_media%%The way the scale armor works is that when in contact with a force, the scales converge inward upon one another to form a...

    New laser technique images quantum world in a trillionth of a second

    %%item_media%%For the first time, researchers have been able to record, frame-by-frame, how an electron interacts with certain atomic vibrations in a solid. The technique...

    Stardust from red giants

    %%item_media%%Some of the Earth's building material was stardust from red giants. Astronomers can also explain why the Earth contains more of this stardust than...

    How to induce magnetism in graphene

    %%item_media%%Graphene, a two-dimensional structure made of carbon, is a material with excellent mechanical, electronic and optical properties. However, it did not seem suitable for...